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Abstract: Dialysis and nutrition are two sides of the same coin—dialysis depurates metabolic waste
that is typically produced by food intake. Hence, dietetic restrictions are commonly imposed in
order to limit potassium and phosphate and avoid fluid overload. Conversely, malnutrition is
a major challenge and, albeit to differing degrees, all nutritional markers are associated with survival.
Dialysis-related malnutrition has a multifactorial origin related to uremic syndrome and comorbidities
but also to dialysis treatment. Both an insufficient dialysis dose and excessive removal are contributing
factors. It is thus not surprising that dialysis alone, without proper nutritional management, often fails
to be effective in combatting malnutrition. While composite indexes can be used to identify patients
with poor prognosis, none is fully satisfactory, and the definitions of malnutrition and protein
energy wasting are still controversial. Furthermore, most nutritional markers and interventions
were assessed in hemodialysis patients, while hemodiafiltration and peritoneal dialysis have been
less extensively studied. The significant loss of albumin in these two dialysis modalities makes it
extremely difficult to interpret common markers and scores. Despite these problems, hemodialysis
sessions represent a valuable opportunity to monitor nutritional status and prescribe nutritional
interventions, and several approaches have been tried. In this concept paper, we review the current
evidence on intradialytic nutrition and propose an algorithm for adapting nutritional interventions to
individual patients.
Keywords: hemodialysis; hemodiafiltration; albumin; Kt/V; malnutrition; elderly; comorbidity; MIS
index; dialysis efficiency
1. Introduction
Towards an unrestricted, personalized approach to diet in dialysis patients.
Dialysis and nutrition are two sides of the same coin—dialysis depurates the metabolic waste that
is typically produced by food intake; hence, dietetic restrictions are commonly imposed on dialysis
patients in order to limit, in particular, potassium and phosphate and avoid fluid overload [1–9].
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This restrictive approach is being increasingly challenged, however, since it makes the difficult
life of dialysis patients even harder, and the generic nutritional restrictions prescribed have significant
limitations and side effects (Table 1) [1,2,10–12].
Table 1. Limiting food versus allowing liberal nutrition in dialysis patients.
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Legend: CKD: chronic kidney disease; PTH parathyroid hormone.
The most common foods that nephrologists, nurses, and patients believe should be limited or
avoided are those rich in potassium, phosphate, and sodium [3–5,7,13–15]. However, these restrictions
are virtually incompatible with a healthy diet (rich in plant-based food), high protein intake (coupled
with phosphate intake), and high calorie intake (associated with varied and good-tasting food) [4–10].
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Furthermore, recent studies have shown that the current food tables do not take additives into
account, and that phosphate and potassium content of processed foods may be significantly higher.
Moreover, added phosphate or potassium are rapidly bioavailable and potentially more toxic [16–20].
Incremental dialysis, aimed at respecting residual kidney function, and intensive dialysis, aimed
at improving efficiency, may be ways to counteract the need for restricted diets, keeping in mind that
standard indications apply only to thrice-weekly “conventional” hemodialysis [21–26].
However, the risk of depletion of important nutrients during dialysis sessions with highly
permeable membranes cannot be ruled out, and, while the advantages of better depuration are clear in
young, well-nourished patients, it is still far from certain that high flow hemodiafiltration produces
advantages for malnourished patients [26–33].
The definitions of malnutrition and protein-energy wasting (PEW) in dialysis patients is neither
simple nor universally agreed upon. Each marker or evaluation proposed has limitations and, as a result,
not all clinicians and authors adopt the same markers to assess nutritional status [34–48].
Even the terms indicating nutritional status in dialysis patients have changed: cachexia,
malnutrition, protein energy wasting, and malnutrition inflammation syndrome (MIA) are all used
to describe dialysis patients, sometimes with similar meaning, sometimes with different nuances
(Table 2) [34–48].
Table 2. Some definitions of “malnutrition” in dialysis patients.
Definitions Advantages Limits
Malnutrition
Intuitive and comprehensive; replaces
the obsolete term “denutrition”,
highlighting the importance not only
of quantity of food but also of its
distribution and quality.
The definition has changed over time,
and the term is usually employed to
describe a combination of muscle
wasting, low nutrient intake, and low
nutritional markers. Its meaning in
the context of “poor quality nutrition”
is often lost.
Generic, too often based on albumin
levels, now recognized as only one of
the markers of malnutrition in dialysis
patients (interference with mode of
dialysis and inflammation). Focuses
attention on intake, and less on causes
of wasting (see below)
Wasting
Proposed in 1983 by the World Health
Organization to define an involuntary
loss of weight of more than 10% in
absence of specific diseases such as
opportunistic infection, cancer, or
chronic diarrhea.
Generic, the time of development is
not univocally defined. Probably more
able to describe rapid changes, which
are not the most frequent in dialysis
patients, in which the process is often
long. Focuses attention on intake,
which may be the result and not the
cause of an underlying process.
PEW: Protein-Energy
Wasting
Widely used. proposed by the
International Society of Renal
Nutrition and Metabolism. Focuses
attention on the relationship between
malnutrition and
metabolic background.
Often only considers albumin and
cholesterol; may be biased in
hyperlipidemia patients and does not
account for the causes of low albumin
levels. Includes BMI, but obese
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According to the Society on
Sarcopenia, Cachexia and Wasting
Disorders (2008), cachexia is a
complex metabolic syndrome
associated with underlying illness and
characterized by loss of muscle, with
or without loss of fat.
According to the International Society
of Renal Nutrition and Metabolism
(2008), cachexia is the last
stage of PEW.
The different definitions make
systematic use of this term difficult.
The Society on Sarcopenia, Cachexia
and Wasting Disorders has introduced
the concept of fatigue, which may be
misleading in severe chronic diseases
and in elderly patients.
Moreover, dialysis prescription varies widely, and very different treatments may be gathered under
the same name; information on the dialysis schedule is often incomplete, thus making comparisons
and implementing strategies can be challenging [29–31].
Long-term interference with lifestyle is a problem. The case of diet and dialysis is a good example
of what is involved. Simplistic approaches often lead to failure; delivering more dialysis, giving more
food, or adding nutrients in the dialysis session may help some patients, but, once more, one size does
not fit all [49–53].
Time spent on dialysis represents about 12 h per week, leaving 156 h “unattended”. This time
may, however, be precious for controlling, teaching, and, at least to some extent, performing nutritional
interventions. Which interventions are more prone to being successful and to what extent is not
clear, since clinical situations, comparators, and type of patients are at least as diverse as the
interventions themselves.
In this concept paper, following a strategy of high adaptation of dialysis schedules, we present
the policy progressively developed in our center and a review of the literature on which it is based.
While formal validation is beyond the scope of this paper, we refer, whenever possible, to the initial
clinical experiences supporting the choices we describe.
2. Intradialytic Nutrition: A Bit of History
When hemodialysis was delivered in 12-h or 8-h sessions using cuprophane membranes, at a time
when hyperkalemia was a frequent cause of death, the dialysis session often represented an opportunity
for patients to eat more liberally. In a population that was mainly young and had low cardiovascular
mortality, except that linked with the effect of long-standing, incompletely corrected uremia, the start
of the dialysis session was often the only time a patient could eat an unrestricted meal [54,55].
This was routinely done in home hemodialysis, but many pioneering centers, practicing long-hour
dialysis, such as the historic one in Tassin, used to give patients a large, rich meal, usually at the start of
dialysis, with the idea that the potentially harmful substances (potassium, phosphate, and salt) would
eventually be depurated during the dialysis session [56].
This policy is still customary in the evening shifts in many centers and for patients on long
dialysis, in which the depletion of phosphate and water-soluble vitamins may warrant the systematic
prescription of nutritional supplements.
When nephroangiosclerosis and diabetes—rather than pyelonephritis and glomerulonephritis—
came to be seen as the causes of end-stage renal disease (ESRD), this was not without consequences for
dialysis tolerance, and the first caveats on eating during dialysis date to this phase. The progressive
shortening of dialysis time, made possible by increased dialysis efficiency, occurred at the same time as
the dialysis population started to become progressively older, a process that is continuing, at least in
many European settings [57–62].
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Furthermore, in the eighties, the decision to shorten dialysis time to 4 h or less led to the widely-held
idea that there was no point feeding patients during dialysis since, in any case, their nutritional status
depended solely on their overall dietary habits. For a number of years, economic and logistic constraints
led to intradialytic interventions being seen as a sort of “hotel” service, more aimed at interrupting
the long dialysis session than addressed to a specific nutritional advantage. However, some centers
continued to allow patients to eat banned foods, such as those rich in phosphate (cheese and ham) or
those rich in potassium (bananas and other fruit), partly as a way to partially compensate for patients’
usual dietary restrictions.
Given growing concerns about malnutrition, the emerging importance of non-compliance with
dietary prescriptions and the logical albeit simplistic conviction that malnutrition in dialysis patients
could be countered by increasing protein and calorie intake, the dialysis session once again came to be
seen as a favorable moment for effective nutritional interventions. Although some authors still claim
that dialysis patients should not eat during treatment, this policy is increasingly being abandoned,
and oral supplementation and intravenous intradialytic nutrition are increasingly being practiced with
a variety of outcomes in different populations [63–67].
While intravenous nutrition was once usually limited to cases of severe malnutrition, the use of
oral intradialytic nutrition as a means of preserving long-term nutritional status is being reported in
a growing number of studies.
3. From the “Skeleton Man” to the Obese Sarcopenic Patient
In the collective imagination, when we think about malnutrition on dialysis, the “skeleton man”
is probably the first image that comes to mind; this evocative and somehow crude definition dated
to the early dialysis era in which cachexia was frequently an effect of under-dialysis in a young
person with high metabolic needs. The combination of insufficient depuration, by itself exerting
a catabolic effect, and of multiple alimentary restrictions led to protein energy wasting, resulting in
a metabolic disaster [68–70].
At least in settings where dialysis efficiency has been a key goal in recent decades, the “skeleton
man” is now seldom encountered in dialysis wards, except in cases in which diffuse and severe vascular
disease is accompanied by a reduction in food intake, often in a context of cognitive impairment in
elderly patients [71–74]. Another exception is patients with a very long dialysis follow-up, whose
clinical situation is often dominated by diffuse precocious bone or vascular disease [75–80] (Figure 1).
However, it is not unusual to find that these thin, fragile patients have very high dialysis efficiency,
often linked to their low BMI and volume distribution, whose dialysis prescription should probably
be decreased rather than increased [29,30]. These cases, particularly the Japanese school, suggest
modulating dialysis efficiency to avoid loss of precious nutrients.
At present, the type of malnutrition most commonly encountered, at least in European settings,
is sarcopenic obesity [81–83]. Although overweight or obese, patients present a severely reduced
muscle mass, often with preserved calorie and protein intake (Figure 2). These cases are difficult
to label; they are not malnourished in the usual sense, they do not have energy wasting, their BMI
is normal, and their calorie intake is usually normal as well. Often, they do not have clear signs of
malnutrition/PEW according to the standard parameters, such as prealbumin or transferrin levels,
and their albumin levels may be modulated more by type of dialysis than by other means. Yet, they have
a severely reduced muscle mass, and this reduction is correlated with survival [81,84–87].
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Figure 1. Diffuse vascular calcifications in a patient with more than 30 years of follow-up on dialysis 
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nutrition and intradialyitic exercise, seen to be the (missing) factor capable of transforming a 
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is no consensus on the best way to deliver it (in cases where it appears to be a viable alternative). A 
severe lack of reliable information makes the prescription of intradialytic nutrition even more empiric 
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The concept on which this paper is based can be summarized as a tailored approach to intradialytic 
nutrition based upon the patient’s clinical characteristics and nutritional status. This “ladder approach”, 
depicted in Figure 3 and discussed below, is the logical complement of a tailored approach to dialysis 
prescription based on life expectancy, vascular access function, and nutritional status [30]. Interestingly, 
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“softer” hemodiafiltration schedule than the traditional French one [29]. 
In both cases, well-nourished patients are dialyzed with high-performance schemes, whose primary 
goal is reaching high efficiency. Conversely, dialysis intensity is reduced, and treatment schedules are 
“tempered” in very fragile patients for whom tolerance becomes the main goal (Figure 3). 
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4. Intradialytic Nutrition: Pros and Cons
As mentioned, it is never easy to deal with the dialysis population. In addition to the potential
side effects associated with intradialytic nutrition, its use is ill-advised in some situations, and there is
no consensus on the best way to deliver it (in cases where it appears to be a viable alternative). A severe
lack of reliable information makes the prescription of intradialytic nutrition even more empiric than
prescription of the dialysis session itself.
5. The Context and The Concept: A Tailored Approach to Dialysis Prescription
The concept on which this paper is based can be summarized as a tailored approach to intradialytic
nutrition based upon the patient’s clinical characteristics and nutritional status. This “ladder approach”,
depicted in Figure 3 and discussed below, is the logical complement of a tailored approach to dialysis
prescription based on life expectancy, vascular access function, and nutritional status [30]. Interestingly,
a paper on a similar approach was recently published by Japanese nephrologists known to pursue
a “softer” hemodiafiltration schedule than the traditional French one [29].Nutrients 2020, 12, 785 7 of 25 
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restoring the nutritional balance. Intradialytic i.v. nutrition is an option in phases in which oral 
alimentation is low but the metabolic machine is not shut off, as witnessed by normal pre-albumin levels. 
Albumin may be needed when the low prealbumin levels suggest a very limited anabolic potential, not 
simply due to the lack of substrates, but usually linked to inflammation of acute diseases. 
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Natural solutions are usually better than artificial ones; this seems also to be the case for the 
choice of modulating the intake of regular food for hemodialysis patients, taking advantage of 
dialysis sessions to combine nutritional interventions and physical rehabilitation.  
The decision to use regular food has two main advantages: allowing patients to choose what 
they actually like best (thus making the usually far from enjoyable dialysis routine a bit more 
bearable) and lower cost. Furthermore, choosing food wisely is more in line with a healthy dietary 
approach, taking into account not only the quantity of nutrients that are consumed but also their 
quality, and avoiding preserved and modified foods. 
The experiments reported in the literature are protean, and the foods included vary. They seem 
to have been chosen mainly for their high protein content (for example, a preparation based on egg 
white in a recent Chinese study) or, less frequently, because of their cultural acceptance and higher 
palatability, as in a Brazilian experiment in which patients were given red meat snacks during dialysis 
[65–68,106–110]. Combination with phosphate binders is sometimes a choice, similarly to what is 
advised in phosphate-rich meals for people who are not on dialysis [108]. 
Figure 3. A ladder, stepwise approach to interdialytic nutrition. In the first steps of the ladder,
when nutritional markers are still ormal, healthy food is advised to maintain nutritional status.
Oral complements are n ed when e ite is low and wh n energy and protein dense food may
help restoring the nutritional balance. Intradialytic i.v. nutrition is an option in phases in which oral
alimentation is low but the metabolic machine is not shut off, as witnessed by normal pre-albumin
levels. Albu in may be needed when the low prealbumin levels suggest a very limited anabolic
potential, not simply due to the lack of substrates, but usually linked to inflammation of acute diseases.
In both cases, well-nourished patients are dialyzed with high-performance schemes, whose primary
goal is reaching high efficiency. Co versely, di lysis intensity is reduced, and treatment schedules are
“tempered” in very fragile patients for whom tolerance becomes the main goal (Figure 3).
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6. Concept and Context: A Special Case, Incremental Hemodialysis
The idea that, in dialysis, “more is better” is not true for fragile patients. The failure of early
dialysis start, which was previously considered synonymous with “healthy” dialysis start, to improve
patients’ prognoses, the recognition of the importance of residual kidney function in determining
survival, and the association of the latter with better nutritional status are all elements in favor of
a progressive, incremental dialysis start aimed at reducing dialysis-related morbidity and mitigating
“dialysis shock” [21–23,94–99].
There is disagreement about the definition of incremental dialysis regarding the number of sessions
there should be per week and what their scheduling and sequence should be (starting with shorter
sessions, increasing frequency first and duration later or starting with fewer sessions of longer duration).
Consequently, nutritional indications must once more be contextualized and adapted [21–23,99–102].
As for nutrition, two almost opposite options are reported in the literature. The first holds
that, regardless of dialysis frequency, all patients who start dialysis should be counseled to follow
a high-protein diet to combat the ever-present threat of malnutrition; the second progressively liberalizes
the diet as the number of dialysis sessions increases [103,104]. Each approach has a logical basis,
but some evidence supporting the second option comes from Italy, where incremental dialysis was
recently reintroduced, and nutritional predialysis care is widespread [16,103,105]. Patients often
start dialysis after following a moderately protein-restricted diet, a policy that is not usual in other
European countries and the United States. In these countries, incremental dialysis prescription is
aimed principally at favoring adaptation by the patient to the new treatment, both from clinical and
psychological points of view. While, in the first case, progressive liberalization of the diet may be seen
as a partial compensation of prior protein restriction, in the second one, reducing protein intake would
only add to the patient’s difficulties in complying with the new, already intrusive treatment.
7. The “Ladder Approach” to Intradialytic Nutrition
Our basic idea was to adapt a stepwise approach in which nutritional supplements or intradialytic
food would be managed with a larger choice for well-nourished patients, up to intravenous
supplementation of albumin, in selected cases with severe hypoalbuminemia and a catabolic status.
Nutritional improvement would make it possible to go back from intravenous to oral supplements
and regular food (Figure 3). The better the patient’s nutritional status or the more improvement being
shown, the more the patient is allowed to determine their dietary choices (Figure 3).
8. Eating “Normal” Food During Dialysis
Natural solutions are usually better than artificial ones; this seems also to be the case for the
choice of modulating the intake of regular food for hemodialysis patients, taking advantage of dialysis
sessions to combine nutritional interventions and physical rehabilitation.
The decision to use regular food has two main advantages: allowing patients to choose what they
actually like best (thus making the usually far from enjoyable dialysis routine a bit more bearable) and
lower cost. Furthermore, choosing food wisely is more in line with a healthy dietary approach, taking
into account not only the quantity of nutrients that are consumed but also their quality, and avoiding
preserved and modified foods.
The experiments reported in the literature are protean, and the foods included vary. They seem
to have been chosen mainly for their high protein content (for example, a preparation based on
egg white in a recent Chinese study) or, less frequently, because of their cultural acceptance and
higher palatability, as in a Brazilian experiment in which patients were given red meat snacks during
dialysis [65–68,106–110]. Combination with phosphate binders is sometimes a choice, similarly to
what is advised in phosphate-rich meals for people who are not on dialysis [108].
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Whatever the reasons for choice and the food offered, eating during dialysis sessions seems to do
more good than harm, provided the patient is not hemodynamically instable and that dry weight is
carefully assessed to avoid hypotension, nausea, and vomiting [64].
According to our algorithm, modulation of intradialytic meals or snacks is the first step to
preserving nutrition in patients with a good nutritional status and to improving it in those cases in
which initial signs of protein energy wasting or sarcopenia are likely to be reversible with combined
nutritional and dialysis approaches integrated wherever possible by physical exercise (Figure 3).
Following this hypothesis, in our center, we attempted to improve compliance by offering patients
a greater variety of food choices and adopted a combined nutritional and educational approach aimed
at improving protein and calorie intake as far as possible in patients with normal or moderately
increased BMI as well as the protein intake in those with obese sarcopenia. Patients are allowed
to choose intradialytic food from a varied “menu” of snacks that are rich in protein and/or calories
(Figure A1 in the Appendix A).
There are many cultural, economic, and logistic barriers to what is the simplest and probably the
safest way to increase food intake and combat malnutrition. Culturally, in a medicalized society, the use
of “normal food” may not be seen as medical treatment, and it may be difficult to convince the hospital
management to offer dialysis patients a rich choice of snacks and meals. Furthermore, the logistics of
a dialysis ward are not always suitable for preparing snacks for patients, and food management may
not be one of the tasks included in the routine activities of a dialysis center. The decision to let patients
bring their own snacks is feasible, but this policy may not work for those patients who are most in
need (elderly, living alone, anorectic, etc.). Economic issues are often raised, yet food is usually less
expensive than oral nutritional supplements, and our opinion is that the organizational problems can
be overcome with little economic burden and great advantage for patients’ well-being.
9. Oral Nutritional Supplements
The idea that fragile or elderly patients need assistance when they eat and that highly
concentrated food supplements can facilitate intake of needed nutrients appears to be a reasonable one;
these supplements are rich in proteins and calories, well standardized, and do not require preparation.
Furthermore, a rich formulation is usually concentrated in a small amount of liquid or is semisolid.
This is an advantage for patients who are anorectic, unable to eat a large amount of food, or have no
specific food preferences, so that giving them oral supplements is an easy way to ensure that they
obtain the recommended quantities of calories and proteins (Table 3).
Many dialysis units now offer these oral supplements, at least to hypoalbuminemic patients,
and a number of studies have addressed their effect on nutritional status and albumin or prealbumin
levels [111–117]. Overall, reports are favorable on all outcomes tested; an interesting suggestion is
the fact that providing oral nutritional supplements during dialysis seems to reduce the number of
missed dialysis sessions, thus underlining the psychological importance that nutritional care has for
our patients [116].
However, these advantages are at least partly counterbalanced by the presence of side effects.
Most of the available nutritional supplements are sweet, and this may be a problem for those patients
who do not like sweet-tasting food and who, in the long run, tend to avoid them. The high energy
content may have the effect of limiting the intake of normal food. Furthermore, in most commonly
available formulations, phosphate is not restricted; there are no restrictions on additives and taste
enhancers whose toxicity is only partially known and could be higher in dialysis patients. No less
importantly, they are expensive (in France between €2 and €5 per supplement), and the price is usually
higher for the more specific formulations needed by dialysis patients.
In our center, during dialysis, we include a choice of oral supplements along with snacks (Figure A1
in the Appendix A). We try to orient patients with lower albumin levels towards protein-rich options
while remembering that personal choice and dietary variation are fundamental for attaining compliance.
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Concomitant dialysis may make it
possible to reduce the risk of fluid
overload; if meals or snacks are given
at the start of treatment, excess
phosphate or potassium can be
removed during the dialysis session.
We lack data on interference with
dialysis efficiency. Low tolerance
(hypotension) can lead to shortened
dialysis time, or reduced blood flow
and dialysis efficiency.
Long-term effects Small studies report good results inselected patients.
Long-term advantages are not clear in




Good, unless the patient develops
hypotension during or immediately
after the meal.
Old studies suggest withholding food
during dialysis. However, high-
protein, high-fat meals were often
supplied, and weight loss was
often considerable.
Losses during dialysis Probably minimal. No clear contraindication.
Additives and
preservation agents
Widely used in industrial food
processing to reduce contaminations
and enhance duration.
Very little studied; while phosphate
and potassium containing additives
are usually avoided less is known
about other substances and trace
elements. This is a question that needs
further study.
From a nutritional point of view, dialysis induces a negative nitrogen balance, hence oral
intradialytic supplements are also an option for well-nourished patients, compensating for the
loss of proteins and amino acids during hemodialysis sessions. In addition to increasing protein
intake, other options for reducing amino acid losses during dialysis include higher carbohydrate
intake, inducing insulin secretion, and lowering amino acid circulating levels and hence their loss
in dialysate [118–120].
10. The “Case” of Ketoacid and Amino Acid Supplementation
Amino acid mixtures have been employed in a number of studies to enrich the protein content of
the food dialysis patients are offered; their advantage, if any, over other options is not clear, and logistics
is probably the most important factor in preferring this approach [121].
In the pre-dialysis phase, plant based, low, or very low protein diets supplemented with
a mixture of essential amino acids and ketoacids are generally associated with a slower progression
of chronic kidney disease (CKD), and some data on the chronic use of these supplements in dialysis
patients are promising with respect to the preservation of residual kidney function and urine volume
output [122–125]. We therefore consider the use of this formulation in dialysis patients with low protein
intake and low albumin levels and who prefer “pills” to other oral supplements.
The only formulation presently available in France is Ketosteril, which consists of film-coated
tablets containing ketoanalogues in forms of calcium salts—a-ketoanalogue of isoleucine, leucine,
phenylalanine, valine, methionine—and the following amino-acids: lysine, threonine, tryptophan,
histidine, and tyrosine. The usual dose, as a complement of low protein diets, is one tablet each
5–10 Kg, according to the level of protein restriction. The dose in dialysis patients is not clearly stated;
the addition to intradialytic snacks is now under evaluation. While the drawback is the addition of
“more pills” to our patients’ already large tablet intake, the advantage is they are less likely to interfere
with appetite, thus possibly better preserving spontaneous food intake.
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11. Intravenous Formulations
The dialysis session is a good opportunity for intravenous administration, useful from the
nutritional point of view when food intake is inadequate. A number of studies, in fact, suggest
that, in selected patients, intradialytic intravenous nutrition can improve the nutritional status of
malnourished dialysis patients in the short-medium term [126–130].
Once more, things are not as simple as they seem; adding intravenous nutritional fuel to
a malfunctioning metabolic machine is not always effective (Table 4). On the one hand, the utilization of
proteins may be impaired by a shut-off anabolic phase, and amino acids may reduce appetite and increase
urea and acidosis if not correctly utilized. Sugars may aggravate the glucose intolerance encountered in
dialysis, and the role of triglycerides, often added as calorie fuel to the intravenous mixture, in worsening
atherosclerotic lesions is not clear. Nausea, muscle pain, infections, hyperglycemia, and complications
linked to the dialysis procedure have occasionally been reported [126–136]. While baseline dyslipidemia
is a contraindication for treatment, no target level based on an evidence-based position has yet
been fixed [128].




Concomitant dialysis makes it
possible to reduce the risk of
fluid overload.
We lack data on interference with dialysis




Tolerance can be regulated
by management.
Tolerance may be low (hyperosmolar media).
Dyslipidemia is a reported contraindication,
but few studies select for this item.
Losses during dialysis The metabolic balance is positivein clinical studies.
The quantity lost is not clear; the use of
parenteral nutrition mainly in the last hour(s)
of dialysis can reduce loss, but interaction
with the dialysis membranes is not clear.
Prescription modalities
Different products are available,
potentially allowing
personalization of treatment.
Experience with “nonconventional dialysis”
is minimal. Re-feeding can be a
life-threatening problem in dialysis patients.
Short-term effects
Small trials report good results in
selected patients. These have not
been confirmed in large
meta-analyses.
The metabolic machinery needs to be at least
partially preserved to make it possible to
exploit the anabolic potential of the substrates.
This may not be the case for patients with
acute problems or severe inflammation, in
which excess non-metabolized proteins may
increase acidosis and urea levels.
Long-term effects
Small trials report good results in
selected patients. These have not
been confirmed in large
meta-analyses.
Long-term effects are not clear in pooled data,
possibly due to the heterogeneity of
indications and populations.
Some studies report an even higher mortality
rate in patients treated with
intradialytic nutrition.
There are several available intravenous preparations differing in concentration and nutrient
balance. On average, an intradialytic infusion of about 1 L of intravenous supplement provides
800–1200 kcal in the form of glucose, lipids, and amino acids, which, on average, are between 30 and
60 g per liter; however, the quantity of nutrients lost in the dialysis procedure is not at all clear [128].
While administration is usually limited to the last hour(s) of dialysis, when the dialysis membrane
is probably less permeable, due to the “protein cake” that partly saturates its capacity to dialyze
molecules of higher molecular weight, we were not able to retrieve any comprehensive study on this
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question. Their cost, estimated as 10 to 100 times higher than oral supplements, further limits their use,
at least in settings where these supplements are not reimbursed [129].
We therefore suggest that that these supplements can be useful in the short-medium term for
patients that, in spite of low food intake, may be able to reverse the metabolic balance from catabolism to
anabolism. Naturally, their limits need to be acknowledged, as does our lack of sound evidence in favor
of any change in hard outcomes [126–129]. Furthermore, since the losses are higher in hemodiafiltration,
when specific techniques including endogenous reinfusion are not available, the advantages of better
depuration of the middle molecules including those involved in inflammation have to be weighed
against the use of hemodialysis so that the metabolic advantages, particularly those of amino acid
supplementation, are not lost [130,131].
12. Albumin (And Blood Transfusions)
When a dialysis patient is under profound metabolic stress, as in the case of an acute disease
or surgery, a rapid, drastic reduction in serum albumin is often observed, together with a dramatic
reduction in prealbumin and hemoglobin. These alterations, often accompanied by profound
deterioration of general well-being, are not likely to respond to an increase in dietary intake or
to an adaptation of the dialysis schedule. The low prealbumin level is evidence of low metabolic
reactivity and is usually closely linked to the patient’s inflammatory status and overall clinical condition.
Not surprisingly, in these acute phases, in which the metabolic machine has shut down, intradialytic
infusion of amino acids and lipids has little effect on nutritional status [126–129].
Similarly, blood transfusions are occasionally needed when, in spite of an increase in erythropoiesis
stimulating agents and the correction of vitamin deficits and iron stores, a patient remains severely
anemic. This is most frequently observed in the same patients that fail to respond to dietary
or intravenous supplementations. In these cases, most commonly in the context of acute or
chronic inflammatory states and the malnutrition-inflammation-atherosclerosis syndrome, transferrin
saturation and reticulocyte count are low in the presence of high ferritin levels and are evidence of
a lack of metabolic response [132–135].
The pattern of low albumin level with a severely depressed prealbumin level is frequently
concomitant. The meaning of infusion of albumin during dialysis in this context is similar to the
infusion of albumin in the case of ascites drainage in cirrhotic hypoalbuminemic patients. Although
the practice of albumin infusion in severely depleted dialysis patients is probably more frequent,
there are very few studies that address this question. [136,137]. As in many cases of severely ill patients,
both beneficial and negative effects are difficult to ascertain. Once more, the problem is the same as
the one encountered when using albumin for cirrhotic patients, a practical choice that is not fully
supported by clear-cut evidence.
While there are even fewer evidence-based studies on albumin infusion in dialysis patients,
the few available ones suggest, as is logical to expect, that albumin infusion may have a favorable effect
on intradialytic hypotension and a low risk of side effects. However, the advantages in the management
of hypotension compared to saline infusion are not clear and probably cannot be generalized [135–140].
The high costs, the potential side effects, and, in particular, the risk of allergic reactions, need to
be underlined.
In our experience with a high comorbidity population, we have employed albumin infusion in
highly selected cases with low albumin, low prealbumin, and high inflammatory markers, usually
following surgery or severe infection. In most of these cases, hypotension was symptomatic and
impaired the attainment of correct depuration. In this context, no allergic reactions were observed
during over 1000 dialysis sessions in which infusion of albumin was practiced over three years
of activity (about 50,000 dialysis sessions), possibly also because of the anergic state that usually
accompanies severe malnutrition.
Albumin infusion is now being increasingly performed in the context of rheopheresis coupled
with dialysis, an emerging technique for the treatment of severe vascular diseases including
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calciphylaxis, a disease typical of fragile dialysis patients with a combination of risk factors including
immunologic diseases, inflammation, sarcopenic obesity, atherosclerosis, underdialysis, and deranged
calcium-phosphate balance [141,142].
13. Are We Doing All We Can? The Role of Intradialytic Exercise
The missing element in the definition of the metabolic pattern of dialysis patients is physical
activity. Metabolic balance is, in fact, significantly affected by physical exercise, which is a well-known
modulator of the anabolic versus catabolic balance in kidney disease patients [143–148].
To be effective, nutrient intake must administered in an anabolic setting, and physical exercise is
the only modifiable anabolic stimulus for muscle tissue.
While an in-depth discussion of the potential role of intradialytic exercise in this context is beyond
the scope of the present review, the association of physical activity should probably be proposed on
a similar scale, from rehabilitation exercises for fitter individuals to mild exercise during dialysis for
those who are more fragile and have less support at home and to passive exercise for the patients who
are in poor clinical condition [149–156].
Clinical limitations, economic constraints, and cultural nihilism have been significant barriers to
the systematic implementation of physical exercise in the dialysis ward, but the concept that physical
activity is a necessary complement of nutritional management is increasingly being accepted and
should be borne in mind when setting up a nutritional support program in a dialysis ward [46].
14. What This Review Did Not Address
This review did not try to define malnutrition or the best way to monitor it, limiting discussion
to controversial practical clinical points [157–159]. The issue of diagnosing and staging malnutrition
would need a dedicated review paper of its own. To give an idea of its complexity, Table 5 summarizes
some of the different means commonly used to evaluate nutritional status in dialysis patients.
Furthermore, the review does not address enteral nutrition, since this choice is usually proposed
not only during the dialysis session and, in our experience, the indication for enteral nutrition came
from problems not strictly related to the dialysis performance. While this approach seems to be
associated with some improvement in different studies, we believe that, at least in our setting, it is very
poorly accepted by patients, and this low cultural acceptance might negatively interfere with other
nutritional strategies [160].
Another question the review did not address is the use of anabolic drugs, such as steroids or growth
hormones, limiting the discussion to “non-pharmacologic” nutritional interventions. The use of anabolic
steroids can indeed be considered in selected cases, at least for short periods, but the potential side
effects should limit the prescription of these non-routine interventions to particular cases [50,161–164].
Another suggestion is the use of β-hydroxy-β-methylbutyrate (HMB), a metabolite of leucine
able to counteract protein degradation, increase protein synthesis by inhibition of proteasome and
stimulation of mTOR pathway, increase the number of mitochondria, and reduce pro-oxidant and
inflammatory status. Improvement of sarcopenia and preservation of muscle function are potential
effects of HMB supplementation [165–167]. While studies performed in fragile or sarcopenic elderly
people are promising on muscle mass and on muscle strength and function, studies in dialysis patients
are lacking. A double blind, placebo-controlled, randomized trial of daily HMB supplementation
up to six months induced no significant advantage in dialysis patients, but a larger scale trial is
needed [167]. Intradialytic creatine supplementation has also been proposed as an alternative to
improve muscle mass and well-being. Once more, there is need for large studies to validate these
potentially revolutionary approaches [168,169].
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Table 5. Nutritional evaluation in dialysis patients: some advantages and limits of the common tests.
Suggested Frequency Advantages Limits
Anthropometry
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performed at least 15
min after the end of the
dialysis; patients may be
reluctant to wait; the cost
of the electrodes is
relatively high. Difficult
to standardize in patients
with amputation or skin
problems. Has to be
interpreted with caution
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effective dietary intake
and adherence to dietary
prescriptions
All the main nutritional
markers are affected not
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and by the inflammatory
status. Interpretation
may be difficult,











tools for dialysis patients,
useful to compare
different series.
SGA is very sensible to
rapid changes, may be
less sensitive to chronic





nutrition may be difficult
to enucleate.
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Table 5. Cont.









The evaluation of dietary







The recall may be biased
or difficult in patients
with cognitive
impairment. Compliance
to dietary journals may
be difficult. Food
frequency questionnaires
are often very sensitive
to the cultural context
and may be difficult to












Sensitive to the burden
of comorbidity.
Performance Tests







Useful to monitor the
effects of a nutritional
intervention; hand-grip
test is increasingly used
to evaluate force as an
indirect measure of
muscle mass.
The tests are reliable only
in experienced hands.
Hand grip tests may be
performed in different
ways, and may be
affected by the presence
of an arterio-venous
fistula or graft.
While acknowledging that malnutrition is usually linked to a patient’s comorbidity and not to the
simple lack of alimentation and underlining the importance of inflammation in the development of
clinical malnutrition in our patients, this review does not touch on the issue of how to avoid or reverse
the dialysis-related inflammatory syndrome, which is clearly one of the main, often unmet goals of
treatment for chronic dialysis patients [170].
15. Final Considerations
Restoring or preserving good nutritional status in dialysis patients is not easy, since what can
broadly be called malnutrition is usually the result of complex metabolic derangements as well as of
severe comorbidities.
There are several non-nutritional reasons for this particular dialysis-related syndrome of which
malnutrition or protein energy wasting are only one aspect, while inflammation, comorbidity, lack of
physical exercise, and insufficient dialysis all contribute to determining the clinical picture. It is therefore
highly unlikely that a simple increase in food intake will be a panacea.
While nothing is simple in dialysis, the fact that patients are seen three times per week during
treatment sessions leaves room for tailored interventions.
The present concept paper suggests employing a stepwise approach against malnutrition in dialysis,
starting from nutritional counseling, trying to increase the intake of healthy food, exploiting the potential
of intradialytic snacks, followed by nutritional supplements, choosing between different combination,
favoring snacks rich in energy or in proteins, upgrading to intradialytic intravenous nutrition, and
leaving albumin infusion as a last resort in patients who are metabolically non-reactive and severely
malnourished patients. Ideally, albumin and intravenous nutrition should be discontinued after
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nutritional improvement, with the final aim of downgrading the intervention to oral supplements and
eventually to increased quantity of healthy food. Employing all the available means in a patient-adapted
and, whenever possible, a patient-friendly way may help to slow the downwards nutritional and
clinical spiral often observed in dialysis patients.
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Figure A1. Tailored approach to intradialytic oral nutrition. A multiple choice menu for dialysis 
patients, allowing a selection of combination of energy or protein dense food. 
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166. Holeček, M. Beta-hydroxy-beta-methylbutyrate supplementation and skeletal muscle in healthy and
muscle-wasting conditions. J. Cachexia Sarcopenia Muscle 2017, 8, 529–541. [CrossRef] [PubMed]
167. Fitschen, P.J.; Biruete, A.; Jeong, J.; Wilund, K.R. Efficacy of beta-hydroxy-beta- methylbutyrate
supplementation in maintenance hemodialysis patients. Hemodial. Int. 2017, 21, 107–116. [CrossRef]
[PubMed]
Nutrients 2020, 12, 785 25 of 25
168. Wallimann, T.; Riek, U.; Möddel, M. Intradialytic creatine supplementation: A scientific rationale for
improving the health and quality of life of dialysis patients. Med. Hypotheses 2017, 99, 1–14. [CrossRef]
[PubMed]
169. Kreider, R.B.; Kalman, D.S.; Antonio, J.; Ziegenfuss, T.N.; Wildman, R.; Collins, R.; Candow, D.G.; Kleiner, S.M.;
Almada, A.L.; Lopez, H.L. International Society of Sports Nutrition position stand: Safety and efficacy of
creatine supplementation in exercise, sport, and medicine. J. Int. Soc. Sports Nutr. 2017, 14, 18. [CrossRef]
[PubMed]
170. Jankowska, M.; Cobo, G.; Lindholm, B.; Stenvinkel, P. Inflammation and Protein-Energy Wasting in the
Uremic Milieu. Contrib. Nephrol. 2017, 191, 58–71.
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
